Cyclopharm Limited ( (AU:CYC) ) has shared an announcement.
Cyclopharm Limited announced the installation of its Technegas® technology at Brooke Army Medical Center (BAMC) in Houston, Texas, marking the first Department of Defense hospital to adopt this system. This installation is part of a 5-year contract with the US Federal Government, positioning Cyclopharm as a significant player in the US market. The deployment at BAMC, the largest military medical facility in the US, is a strategic move to expand Technegas® usage across other Veteran Administration and DoD hospitals, enhancing Cyclopharm’s market presence and growth opportunities.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that provides nuclear medicine solutions to improve patient care outcomes. The company primarily offers Technegas®, a radiopharmaceutical product used in functional lung ventilation imaging, which is instrumental in diagnosing pulmonary embolism and other respiratory conditions.
YTD Price Performance: -25.32%
Average Trading Volume: 172,004
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$123.9M
See more data about CYC stock on TipRanks’ Stock Analysis page.